349 related articles for article (PubMed ID: 25461627)
1. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
2. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
4. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
6. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
7. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.
Tan M; Wettersten HI; Chu K; Huso DL; Watnick T; Friedlander S; Landesman Y; Weiss RH
Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1179-86. PubMed ID: 25234309
[TBL] [Abstract][Full Text] [Related]
8. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.
Wang S; Han X; Wang J; Yao J; Shi Y
PLoS One; 2014; 9(3):e89848. PubMed ID: 24595136
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
13. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
14. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
[TBL] [Abstract][Full Text] [Related]
15. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
Inoue H; Kauffman M; Shacham S; Landesman Y; Yang J; Evans CP; Weiss RH
J Urol; 2013 Jun; 189(6):2317-26. PubMed ID: 23079374
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Walker CJ; Oaks JJ; Santhanam R; Neviani P; Harb JG; Ferenchak G; Ellis JJ; Landesman Y; Eisfeld AK; Gabrail NY; Smith CL; Caligiuri MA; Hokland P; Roy DC; Reid A; Milojkovic D; Goldman JM; Apperley J; Garzon R; Marcucci G; Shacham S; Kauffman MG; Perrotti D
Blood; 2013 Oct; 122(17):3034-44. PubMed ID: 23970380
[TBL] [Abstract][Full Text] [Related]
17. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
[TBL] [Abstract][Full Text] [Related]
19. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]